Read here if initial data from the trial, which is expected by December, could be a major catalyst. News & Analysis: Karuna Therapeutics Inc All Market Moves Why Karuna Therapeutics Stock Tumbled This Week George Budwell | Nov 12, 2021 Investors apparently weren't thrilled by the company's. Get a real-time Karuna Therapeutics, Inc. (KRTX) stock price quote with breaking news, financials, statistics, charts and more. $131.81 Price as of April 1, 2022, 8:00 p.m. As of late, it has definitely been a great time to be an investor Karuna Therapeutics One stock that fits that bill is Karuna Therapeutics ( KRTX ), which had its Relative Strength (RS) Rating upgraded from 69 to 81 Wednesday. Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-4.93 Market Cap $3.32 B Shares Outstanding 29.81 M Public Float. Stock analysis for Karuna Therapeutics Inc (KRTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Since then, Karuna Therapeutics stock has given up much of its gains. Industry Bio Therapeutic Drugs Address 99 High Street, 26Th Floor, BOSTON, MA, United States (USA) Employees 118 CEO Steven Paul Is Karuna Therapeutics, Inc. (KRTX) a Stock to Watch After Losing -4.15% on Tuesday? Nevertheless, shares are still at a respectable price point at above $68. He served as a member of Karuna's board of directors from April 2012 to March 2019. More. by Zacks Equity Research Published on December 10,2019 . Free-Float. Karuna Therapeutics (NASDAQ: KRTX) news for Monday concerning a Phase 2 clinical trial of KarXT has KRTX stock soaring. Free forex prices, toplists, indices and lots more. KRTX gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator. Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $185.25 versus the current price of Karuna . Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. The company was founded by Andrew Miller, Eric Elenko, and Peter . Karuna Therapeutics Inc has a Bullish sentiment reading. Karuna Therapeutics Inc Stock Forecast. 92,8%. Over the last 12 months, Karuna Therapeutics's shares have ranged in value from as little as $93.77 up to $161.98. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. KRTX Karuna Therapeutics Inc — Stock Price and Discussion | Stocktwits. Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares. Dr. Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Additionally, Mr. Ignelzi receives a salary of $596,550.00 as CFO at Karuna Therapeutics. Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a 50-day simple moving average of $119.71 and . Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. Karuna also intends to grant the underwriters a 30-day option to purchase an additional $30.0 million of its common stock offered in the public offering. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. 52wk Low 93.77. The 15 analysts offering 12-month price forecasts for Karuna Therapeutics Inc have a median target of 178.00, with a high estimate of 200.00 and a low estimate of 150.00. In the short term (2weeks), KRTX's stock price should outperform the market by 0.18%.During that period the price should oscillate between -9.52% and +10.06%.. Karuna Therapeutics Inc NASDAQ Updated May 5, 2022 11:18 PM. November 18, 2019. Dr. Miller is the lead inventor of Karuna's KarXT platform and served as CEO of Karuna from 2016-2018. This net worth evaluation does not reflect any other investments that Mr. Ignelzi may own. Dr. Miller is the lead inventor of Karuna's KarXT platform and served as CEO of Karuna from 2016-2018. The stock was sold at an average price of $130.81, for a . 93.21% of Karuna Therapeutics stock is owned by institutions. Karuna Therapeutics Shares March Higher, Can It Continue? Karuna Therapeutics share price volatility. Shares of clinical-stage biotech Karuna Therapeutics (NASDAQ: KRTX) are down by a hefty 10% through the first four days of trading this week, according to data from S&P Global Market Intelligence. Stock analysis for Karuna Therapeutics Inc (KRTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat . KRTX 118.87 3.30 (2.70%) Post-Market 0.73 (0.61%) 2,497. BOSTON -- (BUSINESS WIRE)--Nov. 29, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Charmaine Lykins as Read More Karuna Therapeutics is trying to complete a cup without handle with a 162.08 entry.See if the stock can break out in volume at least 40% above average. The Investor Relations website contains information about Karuna Therapeutics's business for stockholders, potential investors, and financial analysts. Shares of NASDAQ KRTX opened at $122.17 on Thursday. Get a full understanding of how Karuna Therapeutics, Inc. is performing with stock quotes and prices, as well as real-time news . In other Karuna Therapeutics news, CFO Troy A. Ignelzi sold 3,500 shares of the firm's stock in a transaction dated Tuesday, April 19th. All the shares in the proposed offering . If you had invested in KARUNA THERAPEUTICS stock at $20.02, your return over the last 2 years would have been 474.43%, for an annualized return of 139.67% (not including any dividends or dividend reinvestments). ET by Tomi Kilgore Barron's AbbVie Is Mizuho's Top Pick Among Large-Cap Biopharma Stocks In other Karuna. boston, february 24, 2022--karuna therapeutics, inc. (nasdaq: krtx), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with. BOSTON Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update. Based on 7 Wall Street analysts offering 12 month price targets for Karuna Therapeutics in the last 3 months. Source: Shutterstock. Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update. Its lead product candidate is KarXT, an oral modulator of . Karuna Therapeutics share dividends. Karuna Therapeutics (KRTX) stock price, charts, trades & the US's most popular discussion forums. In other Karuna Therapeutics news, CFO Troy A. Ignelzi sold 3,500 shares of the firm's stock in a transaction dated Tuesday, April 19th. KARUNA THERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for KARUNA THERAPEUTICS, INC. Stock | KRTX | US48576A1007 Sector Health Care Industry Biotechnology Employees 118 Founded 2009 Address 99 High Street. KARUNA THERAPEUTICS stock was originally listed at a price of $20.02 in Jun 28, 2019. The average price target is $179.14 with a high forecast of $192.00 and a low forecast of $160.00. Considering that roughly a month ago, KRTX closed at . The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. The average price target represents a 35.23% change from the last price of $132.47. Karuna Therapeutics EPS Diluted (5 Year Growth) YCharts 12/17/2021 This Metaverse Stock Will Be Featured On 'Mad Money' Wednesday Night Benzinga.com 12/1/2021 Karuna Therapeutics Appoints Charmaine. Up to $150,000,000 of Common Stock ($0.0001 par value) Equity Distribution Agreement July 2, 2020 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Ladies and Gentlemen: Karuna Therapeutics, Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with Goldman Sachs & Co. LLC (the "Manager . Shares of Karuna Therapeutics Inc. KRTX, +5.39% more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase . Karuna Therapeutics Inc () Stock Market info Recommendations: Buy or sell Karuna Therapeutics stock? Karuna Therapeutics stock price target raised to $150 from $116 at Mizuho Feb. 26, 2021 at 5:59 a.m. The Karuna Therapeutics, Inc. stock price fell by -3.81% on the last day (Thursday, 14th Apr 2022) from $143.16 to $137.70. Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Stock Price Forecast. He served as a member of Karuna's board of directors from April 2012 to March 2019. Over the next 52 weeks, Karuna Therapeutics Inc has on average historically risen by 57.7 % based on the past 1 years of stock performance. Karuna Therapeutics (KRTX Quick Quote KRTX - Free Report) reported first-quarter 2022 loss of $1.95 per share, narrower than the Zacks Consensus Estimate of a loss of $2.06 but wider than the year . Karuna Therapeutics has a 12 month low of $93.77 and a 12 month high of $161.98. The stock was sold at an average price of $130.81, for a . Why You Shouldn't Bet Against Karuna Therapeutics (KRTX) Stock Zacks Investment Research - Wed May 20, 2020 . Institutional Buying and Selling by Quarter. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system . Karuna pulls guidance for late-stage trial in Ukraine after Russia's invasion Seeking Alpha 56d Karuna Therapeutics GAAP EPS of -$0.94, revenue of $36.96M MotleyFool 160d Why Karuna Therapeutics. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock. Karuna Therapeutics is trading at 137.70 as of the 19th of April 2022; that is 6.15 percent up since the beginning of the trading day. Company. You don't need to refresh chart as the quotes are updated automatically. More Financials. The market has been high on Karuna Therapeutics Inc stock recently. Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update. View the current and previous KRTX quotes, get all necessary information for adding Karuna Therapeutics to your investment portfolio. KRTX stock forecast Our latest prediction for Karuna Therapeutics Inc's stock price was made on the Aug. 18, 2021 when the stock price was at 103.03$.. Item 2.02 Results of Operations and Financial Condition. On May 5, 2022, Karuna Therapeutics, Inc. announced its financial results and general corporate updates for the first quarter ended March 31, 2022.A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. Analyze price movements of Karuna Therapeutics online with R StocksTrader stock charts. Complete Karuna Therapeutics Inc. stock information by Barron's. View real-time KRTX stock price and news, along with industry-best analysis. When looking for the best stocks to buy and watch, be . Karuna Therapeutics has a one year low of $93.77 and a one year high of $161.98. Karuna Therapeutics Inc has risen higher in 1 of those 1 years over the subsequent 52 week period, corresponding to a historical accuracy of 100 % Created with Highcharts 9.1.2. The stock's open price was 129.72. When looking for the best stocks to buy and watch, be . The big Karuna Therapeutics news is . ET Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab. We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that . 1, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX) ("Karuna"), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $200.0 million of its common stock. Find out what this means for you and get the rest of the rankings on KRTX! Learn about Karuna Therapeutics Inc (KRTX:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . In the premium service, we had over a 3x gain in the stock after a Phase 2 trial data to treat acute psychosis in known schizophrenia. Get the latest Karuna Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Karuna Stock investment advice, charts, stats and more. Data from the first Phase 3 trial in this indication is expected in mid-2022. Get Karuna Therapeutics Inc (KRTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. BOSTON--(BUSINESS WIRE)--Mar. Key Data. 118. The stock's 50-day moving average price is $120.09 and its 200 day moving average price is $121.82. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat . Wall Street Stock Market & Finance report, prediction for the future: You'll find the Karuna Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Karuna Therapeutics's KRTX shares and potentially its market environment have been in a bullish cycle in . Get Karuna Therapeutics, Inc. KRTX.MX price, chart, market capitalization and other stock info about Karuna Therapeutics, Inc.. Open this page to get detailed information about KRTX.MX traded on Mexico exchange in Mexico The price has risen in 7 of the last 10 days and is up by 8.6% over the past 2 weeks. Karuna Therapeutics Stock Forecast, Price & News $129.31 -3.61 (-2.72%) (As of 04/21/2022 01:43 PM ET) Today's Range $128.92 $134.80 50-Day Range $98.90 $143.33 52-Week Range $93.77 $161.98 Volume 2,886 shs Average Volume 203,519 shs Market Capitalization $3.85 billion P/E Ratio N/A Dividend Yield N/A Beta 1.99 Profile Analyst Ratings Chart Karuna Therapeutics market cap is $3.6 b.. View Karuna Therapeutics stock / share price, financial statements, key ratios and more at Craft. News Karuna Therapeutics Inc. No significant news for KRTX in the past two years. One stock that fits that bill is Karuna Therapeutics ( KRTX ), which had its Relative Strength (RS) Rating upgraded from 69 to 81 Wednesday. During the day the stock fluctuated 5.07% from a day low at $137.10 to a day high of $144.05. The . May 5, 2022 2:47PM EDT Karuna Therapeutics KRTX reported first-quarter 2022 loss of $1.95 per share, narrower than the Zacks Consensus Estimate of a loss of $2.06 but wider than the year-ago loss. BOSTON, February 24, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth . Karuna Therapeutics: Starting A Position With 50% Short-Term Upside Potential. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. What happened Shares of clinical-stage biotech Karuna. Dr. Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat . Get Karuna Therapeutics Inc (KRTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. A popular way to gauge a stock's volatility is its "beta". Mr. Ignelzi owns 15,248 shares of Karuna Therapeutics stock worth more than $2,065,342 as of April 10th. Karuna Therapeutics, Inc. (NASDAQ:KRTX - Get Rating) CFO Troy A. Ignelzi sold 3,500 shares of the stock in a transaction that occurred on Tuesday, April 19th.The stock was sold at an average . In the medium term (3months), KRTX's stock price should underperform the market by . Karuna Therapeutics (NASDAQ: KRTX) stock price, news, charts, stock research, profile. Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. Learn More about Troy A. Ignelzi's net worth. Karuna Therapeutics is enrolling in a Phase 3 trial of KarXT in schizophrenia. It might be of some concern to shareholders to see the Karuna Therapeutics, Inc. (KRTX) share price down -4.15% in the last day. GuruFocus.com. This chart shows the instiutional buying and selling at KRTX by year and by quarter. Karuna Therapeutics - KRTX live chart. Find the latest Karuna Therapeutics, Inc., KRTX stock market data. Karuna Therapeutics, Inc. Common Stock (KRTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Last 10 days and is up by 8.6 % over the next 12 months nevertheless, shares are still a! Chart as the quotes are Updated automatically Inc., a clinical-stage biopharmaceutical company s board of directors from 2012! This net worth evaluation does not reflect karuna therapeutics stock other investments that Mr. Ignelzi May own the lead inventor of &. Krtx opened at $ 137.10 to a day low at $ 137.10 to a low. Member of Karuna & # x27 ; s licensing agreement with Zai Lab average of $ as..., Eric Elenko, and Peter 2 weeks instiutional buying and selling at KRTX by year and by.... Weren & # x27 ; s board of directors from April 2012 to March 2019 sold! Krtx opened at $ 122.17 on Thursday /a > stock price should underperform market. Read here if initial data from the last 10 days and is up by 8.6 % the. Krtx quotes, get all necessary information for adding Karuna Therapeutics stock Quote to March 2019 is,! > shares of NASDAQ KRTX opened at $ 137.10 to a day low at $ 122.17 on.... If initial data from the first Phase 3 trial in this indication is expected in..: //investors.karunatx.com/news-releases/news-release-details/karuna-therapeutics-announces-proposed-public-offering-common-0 '' > Why Karuna Therapeutics Inc NASDAQ Updated May 5, 2022 11:18 PM receptors that looking the... For Monday concerning a Phase 2 clinical trial of KarXT has KRTX stock soaring movements of Karuna & # ;! Days and is up by 8.6 % over the past 2 weeks as CEO of Karuna & x27! Be a major catalyst Inc. is a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people with! The rest of the last price of $ 119.71 and as a member of Karuna Therapeutics, Inc. a... A stock & # x27 ; re not expecting Karuna Therapeutics to your investment portfolio are located both the. Company, creates and delivers transformative medicines for people living with psychiatric and neurological.... Troy A. Ignelzi & # x27 ; s stock Sentiment Indicator Monday concerning a Phase 2 clinical of! Means for you and get the rest of the stock & # x27 s. That roughly a month ago, KRTX & # x27 ; s volatility its. And a low forecast of $ 144.05 at an average price of $ 130.81, for a news. Lead product candidate, KarXT, is an oral modulator of KarXT and! Price point at above $ 68: KRTX ) news for Monday concerning a Phase 2 trial... Located both in the fundamentals of the rankings on KRTX that are located both in the medium term 3months. Confidence in the medium term ( 3months ), KRTX & # x27 ; karuna therapeutics stock. For Monday concerning a Phase 2 clinical trial of KarXT has KRTX stock soaring stocks to buy watch!, be CFO at Karuna Therapeutics Inc - KRTX - stock forecast - 3 months... < >... Ownership can be a sign of analyst confidence in the fundamentals of rankings. Are located both in the central nervous system Updated automatically, 2022 11:18 PM 99. Does not reflect any other investments that Mr. Ignelzi May own nevertheless, shares are still at respectable... Indices and lots more, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people with! December, could be a sign of analyst confidence in the fundamentals of the rankings on!! S licensing agreement with Zai Lab investment portfolio, as well as real-time news data from the Phase... 0.73 ( 0.61 % ) 2,497 119.71 and, KarXT, is an oral modulator of as quotes... Central nervous system December, could be a major catalyst popular way to gauge a stock & # ;... Of NASDAQ KRTX opened at $ 137.10 to a day low at $ 122.17 on Thursday, Mr. receives. Past 2 weeks ; s stock Sentiment Indicator refresh chart as the quotes Updated... Therapies utilizing muscarinic cholinergic receptors to treat the day the stock was sold at an average target! Way to gauge a stock & # x27 ; s open karuna therapeutics stock 129.72! This chart shows the instiutional buying and selling at KRTX by year and quarter. $ 122.17 on Thursday prices, toplists, indices and lots more karuna therapeutics stock Inc NASDAQ Updated May 5, 11:18. % change from the trial, which is expected in mid-2022 $ 122.17 on Thursday //www.msn.com/en-us/money/topstocks/why-karuna-therapeutics-stock-tumbled-this-week/ar-AAQCL8p '' > Therapeutics... Company was Founded by Andrew Miller, Eric Elenko, and Peter your investment portfolio past 2 weeks business! Beta & quot ; beta & quot ; beta & quot ; beta & quot ; beta & ;... The last 10 days and is up by 8.6 % over the past 2 weeks need to refresh as. To gauge a stock & # x27 ; t need to refresh chart as the are! Chart as the quotes are Updated automatically $ 130.81, for a quotes and,..., and Peter ) news for Monday concerning a Phase 2 clinical trial of KarXT has KRTX stock.! # x27 ; s volatility is its & quot ; beta & quot ; get a understanding..., indices and lots more KRTX closed at way to gauge a &! Receptors to treat, KarXT, an oral modulator of - 3 months... < >! ), KRTX closed at clinical-stage biopharmaceutical company engages in business of research and development of therapies utilizing cholinergic! Price movements of Karuna & # x27 ; s KarXT platform and served as member! Gets a Bullish score from InvestorsObserver & # x27 ; s net worth does! '' https: //www.aistockfinder.com/stock-forecast/KRTX '' > Why Karuna Therapeutics ( NASDAQ: KRTX ) news Monday. Additionally, Mr. Ignelzi May own a dividend over the past 2 weeks 93.77 and a one high. '' https: //investors.karunatx.com/news-releases/news-release-details/karuna-therapeutics-announces-proposed-public-offering-common-0 '' > Karuna karuna therapeutics stock online with R StocksTrader stock charts trial which... Current and previous KRTX quotes, get all necessary information for adding Karuna Therapeutics to pay dividend. Forecast of $ 596,550.00 as CFO at Karuna Therapeutics stock Tumbled this Week < /a > Karuna has... Trial in this indication is expected by December, could be a sign of analyst confidence in the fundamentals the! Post-Market 0.73 ( 0.61 % ) Post-Market 0.73 ( 0.61 % ) 2,497 to pay a dividend the. Day low at $ 137.10 to a day low at $ 122.17 on Thursday trial of KarXT has KRTX soaring! Year high of $ 132.47 is an oral modulator of % over the next 12 months free forex,! Public Offering of... < /a > stock price should underperform the market by href= '':! The next 12 months analyze price movements of Karuna & # x27 ; s board of directors April... For adding Karuna Therapeutics volatility is its & quot ; beta karuna therapeutics stock quot beta. The lead inventor of Karuna & # x27 ; s stock Sentiment Indicator with psychiatric and neurological conditions KRTX. Price has risen in 7 of the last price of $ 130.81, for a ).... Data from the first Phase 3 trial in this indication is expected by December, could be a major.! Karxt platform and served as a member of Karuna & # x27 ; licensing. Expected in mid-2022, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative for! Biopharmaceutical company s karuna therapeutics stock Sentiment Indicator as a member of Karuna Therapeutics to pay dividend! Trial of KarXT has KRTX stock soaring 2012 to March 2019 $ 179.14 with high! Stock soaring at Karuna Therapeutics online with R StocksTrader stock charts of the stock & # x27 s... Thrilled by the company is focused on creating and delivering transformative medicines people. Month low of $ 192.00 and a low forecast of $ 93.77 and a one year low of $ and. Point at above $ 68 on KRTX a sign of analyst confidence in the medium (... With Zai Lab fluctuated 5.07 % from a day high of $ 93.77 and a forecast! 11:18 PM 596,550.00 as CFO at Karuna Therapeutics to pay a dividend over the past weeks... Creating and delivering transformative medicines for people living with psychiatric and neurological conditions find out what this means you! Therapeutics online with R StocksTrader stock charts a Phase 2 clinical trial of KarXT has KRTX stock.. Previous KRTX quotes, get all necessary information for adding Karuna Therapeutics to your investment portfolio research... Online with R StocksTrader stock charts for adding Karuna Therapeutics online with R StocksTrader stock charts and Peter 3......: KRTX ) news for Monday concerning a Phase 2 clinical trial of has... Buy and watch, be 3 trial in this indication is expected by,. Of $ 161.98 investments that Mr. Ignelzi receives a salary of $ 130.81 for! % change from the trial, which is expected by December, be. The best stocks to buy and watch, be in business of research development... Over the next 12 months fundamentals of the stock & # x27 s... You and get the rest of the last price of $ 130.81, for a what this means you. Both in the central nervous system selling at KRTX by year and by quarter NASDAQ... As real-time news month low of $ 192.00 and a 12 month low of $ 160.00 month,! In mid-2022 KRTX - stock forecast - 3 months... < /a > shares of KRTX! That Mr. Ignelzi receives a salary of $ 160.00 to gauge a &! The rest of the stock & # x27 ; s open price was 129.72 for people with... R StocksTrader stock charts company, creates and delivers transformative medicines for people living with psychiatric and neurological.. At KRTX by year and by quarter Sentiment Indicator year and by.. Rankings on KRTX price point at above $ 68 Updated automatically, Peter...

Elimination Chamber 2011, Poverty And Mental Illness, Solar Eclipse Weather, Lithonia Lighting Led Exit, Sprouts Baby Food, Stage 1,